Zura Bio Limited (NASDAQ:ZURA) Short Interest Down 21.9% in August

Zura Bio Limited (NASDAQ:ZURA) saw a large drop in short interest in the month of August. As of August 31st, there was short interest totaling 425,300 shares, a drop of 21.9% from the August 15th total of 544,600 shares. Based on an average trading volume of 639,400 shares, the days-to-cover ratio is currently 0.7 days. Approximately 1.0% of the shares of the company are sold short. Approximately 1.0% of the shares of the company are sold short. Based on an average trading volume of 639,400 shares, the days-to-cover ratio is currently 0.7 days.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Two Sigma Advisers LP bought a new stake in shares of Zura Bio in the fourth quarter valued at about $32,000. Savant Capital LLC lifted its holdings in shares of Zura Bio by 190.4% in the second quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock valued at $34,000 after purchasing an additional 21,249 shares in the last quarter. ProShare Advisors LLC bought a new stake in shares of Zura Bio in the fourth quarter valued at about $35,000. AQR Capital Management LLC bought a new stake in shares of Zura Bio in the first quarter valued at about $72,000. Finally, Nuveen LLC bought a new stake in shares of Zura Bio in the first quarter valued at about $76,000. 61.14% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ZURA has been the subject of several analyst reports. Chardan Capital restated a “buy” rating and set a $10.00 target price on shares of Zura Bio in a research report on Friday, August 15th. HC Wainwright cut their target price on Zura Bio from $3.00 to $2.00 and set a “neutral” rating for the company in a research report on Tuesday, August 19th. Finally, Oppenheimer cut their target price on Zura Bio from $17.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $11.60.

Zura Bio Stock Up 7.9%

NASDAQ:ZURA opened at $2.05 on Friday. Zura Bio has a 12-month low of $0.97 and a 12-month high of $5.07. The firm has a market capitalization of $133.29 million, a P/E ratio of -2.93 and a beta of -0.02. The stock’s fifty day simple moving average is $1.77 and its 200-day simple moving average is $1.41.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.02. As a group, equities research analysts expect that Zura Bio will post -0.65 earnings per share for the current year.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.